CHINA – WuXi Biologics has introduced EffiX, an advanced E. coli expression system designed to improve the production of recombinant proteins and plasmid DNA (pDNA).
The demand for microbial-derived biologics is growing rapidly, driven by the need for nanobodies, enzymes, antibody fragments, cytokines, pDNA, antigens, and polypeptides, which play key roles in therapy development.
EffiX addresses the challenges of producing smaller biomolecules by ensuring high yield, stability, and scalability.
The platform can achieve titers of over 15 g/L for recombinant proteins and more than 1 g/L for pDNA, significantly improving production efficiency.
By streamlining processes from early-stage research to commercial manufacturing, EffiX accelerates biotherapeutic development for global partners.
It also integrates a cost-effective chemistry, manufacturing, and controls (CMC) strategy, making biologics production more accessible.
Innovative technology for biologics development
As part of WuXi Biologics’ microbial expression system offerings, EffiX supports Good Manufacturing Practice (GMP) and CMC development.
It provides flexibility at every stage, ensuring reliable production for various therapeutic applications.
CEO Dr. Chris Chen highlighted the platform’s impact: “We are excited to upgrade our microbial solutions with the innovative EffiX platform, which offers exceptional productivity, quality, and scalability. Our commitment to pushing technological boundaries enables global partners to deliver high-quality and affordable biologics faster.”
The launch of EffiX follows WuXi Biologics’ continued efforts to enhance biologics development.
In August 2024, the company partnered with Medigene to advance TCR-guided T-cell engagers, aimed at treating difficult-to-treat tumors.
XRP HEALTHCARE L.L.C | License Number: 2312867.01 | Dubai | © Copyright 2025 | All Rights Reserved